Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors

Poly-(ADP-ribose) polymerase (PARP) inhibitors act through synthetic lethality in cells with defects in homologous recombination (HR) DNA repair caused by molecular aberrations such as BRCA mutations, and is approved for treatment in ovarian cancer, with promising clinical activity against other HR...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Joline S. J., Tan, David S. P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5575612/
https://www.ncbi.nlm.nih.gov/pubmed/28829366
http://dx.doi.org/10.3390/cancers9080109

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5575612/
https://www.ncbi.nlm.nih.gov/pubmed/28829366
http://dx.doi.org/10.3390/cancers9080109

Ejemplares similares